Skip to main content

Laboratory & Diagnostics

Bio-Rad Reports First-Quarter 2025 Financial Results: Strategic Adjustments Amid Market Uncertainty

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – May 8, 2025 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced its financial results for the first quarter of 2025. Despite navigating a challenging macroeconomic landscape, the company demonstrated solid operational performance, underscoring its commitment to driving growth and margin expansion amidst market volatility.

Bio-Rad to Report First Quarter 2025 Financial Results.

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – May 8, 2025 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a recognized leader in life science research and clinical diagnostics products, is set to announce its first-quarter financial results for 2025 on Thursday, May 1, 2025. The company will release its earnings after market close, followed by a detailed conference call to discuss the results.

Mindray FA-N Series: Rapid Diagnosis of Bloodstream Infection with Optimized Workflow

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – May 7, 2025 – Mindray, a global leader in medical technologies, has announced the launch of its new-generation FA-N Series, an advanced automatic microbial culture system designed to transform the diagnosis of bloodstream infections. This cutting-edge system offers optimized workflows, faster detection times, and enhanced accuracy, addressing key challenges faced by clinical microbiologists and improving patient outcomes.

Hologic Reports Financial Results for Q2 Fiscal 2025, Exceeding Revenue Expectations Despite Lowered EPS Guidance

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – May 7, 2025 – Hologic, Inc. (Nasdaq: HOLX), a leader in medical technologies focused on women’s health, today announced its financial results for the second quarter of fiscal 2025. The company reported revenue of $1,005.3 million, slightly surpassing the upper end of its guidance, despite a decline in overall earnings per share (EPS) due to non-cash impairment charges. Hologic’s performance was primarily driven by strong demand in its diagnostics and skeletal businesses, along with ongoing profitability improvements and strategic share buybacks.

BD Innovator Inducted to AIMBE College of Fellows, Strengthening Commitment to Medical and Biological Engineering Advancements

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company), a global leader in medical technology, has announced the induction of Eric Diebold, Ph.D., Vice President and General Manager of Instruments, Software, and Informatics, Biosciences, to the prestigious American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.

BD to Present at Bank of America Securities Health Care Conference

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company), a global leader in medical technology, has announced its participation in the upcoming Bank of America Securities Health Care Conference, scheduled for Tuesday, May 13, 2025, at 1:00 pm Eastern Time. The live webcast of the presentation will be available on the BD investor relations website, with a replay accessible afterward for those unable to attend the live event.

Bupa’s Whole Genome Sequencing Programme Uncovers Genetic Health Risks in 75% of Participants

Submitted by fairsonline´s … on

SHERIDAN, WYOMING – May 5, 2025 – International healthcare leader Bupa has unveiled pivotal insights from its whole genome sequencing initiative, ‘My Genomic Health’, revealing significant hidden health risks in the majority of participants and marking a transformative step in the future of preventive healthcare. Designed to provide personalised, actionable data, the programme is reshaping how genetic information is used to drive early intervention and long-term wellness outcomes in the UK, Spain, and beyond.